In 2010 the Drug Discovery Symposium will encompass eight scientific sessions.

1. Ion Channel Drug Discovery
2. Strategies to Reduce Candidate Attrition
3. Cells and Proteins for Drug Discovery
4. Modern HTS and Assay Development: Views from the Front Line
5. High Throughput Molecular Biology
6. Signalling Pathways: Receptors and Enzymes
7. Drug discovery Automation
8. Diseases in the Developing World

We invite all members of the drug discovery community to attend the Drug Discovery meeting in 2010.

 

 

POSTERS

SLAS (Society for Laboratory Automation and Screening), are Sponsoring the 'Young Scientists Poster Award' at Drug Discovery 2010.

Present a Poster at the show and have the opportunity of winning the prestigious YSP Award. 

Win $500 + a Trip to Palm Springs to present your Poster at ALA Lab Automation 2011 + a chance to publish your work in JALA 

To Submit a Poster please send it to This e-mail address is being protected from spambots. You need JavaScript enabled to view it

 -------------------------------------------------------------------------------------------------------------------------------------------

The Speaker Programme is below.   If you have any questions about this please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it

To apply for a stand at the Innovation Zone contact:  This e-mail address is being protected from spambots. You need JavaScript enabled to view it

To Exhibit click the link below, here you will be able to see the floorplan and book a stand.

• Click here for exhibition booking & floor plan

• Delegates can register for the event, Free of Charge by clicking here

• Click here to download the event flyer

 

SBS SHORT COURSES:   Tuesday 31st August

Course 1
Cell Culture and Fermentation Methods
Chair: Katy Gearing (GlaxoSmithkline)     

Course 2
Introduction to High Content Screening
Chair: Achim von Leoprechting (PerkinElmer)    

Course 3
Introduction to in vitro ADME Screening
Chair: Alison Wilby (AstraZeneca)     

Places are limited.  For Information and Booking please contact This e-mail address is being protected from spambots. You need JavaScript enabled to view it  

10.30 - -6.00pm on Tuesday 31st August.           
 

--------------------------------------------------------------------------------------------------------

Lonza lunchtime tutorials

The Jaguar Suite, Ricoh centre - ground floor

September 1

12.50 - 1.25  -     Primary Sensors: Cell-Based Assays in Primary Cells -          Anthony Pitt
1.30 - 2.05 -       Achieving consistent, high volume primary cell supply -            Alex Batchelor
2.10 - 2.45 -       High throughput Nucleofection® in automated environments -    Dr. Gerhard Muster

  

September 2
 

12.35 - 1.15 -     High-content Analysis of Signaling Networks Enable Predictive Compound Profiling -    Anthony Pitt
1.20 - 2.00 -       Biomarker Discovery -             Dr. Swati Bhattacharyya, Ph.D.

 

 

The tutorials will be held in the Jaguar Suite, ground floor Ricoh centre, across the lobby from the exhibition area (follow the signs).

   Places are FREE - but are limited.   To secure your place pre-register now at www.lonza.com/elrig-dd2010

---

 

GOLD SPONSOR

 

 

SESSION SPONSORS

 

 

MEDIA SPONSORS

 

 

---

 

2010 ELRIG/SBS/BPS   CONFERENCE PROGRAMME  -  RICOH ARENA

1^st – 2^nd September 2010

 

DAY 1 - 1ST SEPTEMBER 2010

	Ion Channel Drug Discovery	Strategies to Reduce Candidate Attrition	Cells and Proteins for Drug Discovery	Modern HTS and Assay Development: views from the front line
SPONSORS	ChanTest and Cambridge Bioscience	Pharma Diagnostics		TTP LABTECH
Session Chairs 9.00 – 9.15	Martin Gosling, Novartis Del Trezise, Essen BioScience	Russell Mortishire-Smith, J & J Alan Watt, Cellzome UK	Katy Gearing, GSK Tom Crabbe, UCB	Richard Eglen, PerkinElmer Lorenz Mayr, Novartis
9.15 - 10.00	TRPA1-antagonists: the next morphine without the side-effects? Neil Hayward, Hydra	Brains and Good Science – no substitutes Colin Dollery, GSK	Cell Culture Technology ―  Past, Present, and Future Ian Freshney, Glasgow Uni	Public-Private partnerships: Opportunities for collaborative research in Drug Discovery and the Medical Research Council Technology Group’s activities. David Tapolczay, MRCT
10.00 - 10.30	Designer peptide neurotoxins for ion channels: phage display using scaffolds found in nature Steve Goldstein, Chicago	Colin Dollery, GSK	Derivation & Utility of Cardiomyocytes from Human Pluripotent Stem Cells   Chris Denning, Nottingham Uni	Application of HTS technology to discover small molecules that can reprogram somatic cells to iPS cells. Kelvin Lam, Harvard, USA
10.30 - 11.15	COFFEE
11.15 - 11.45	TBC	Biomarkers to aid target selection, candidate identification and clinical POC design Chas Bountra, SGC Oxford	Hi-Spots - Functional micro tissues engineered in-vitro from stem cells and primary material for predicting in-vivo efficacy and toxicity Prof Lars Sundstrom, Cardiff University	Screening and Characterisation of Nanobodies:  Where the small molecules meet Biopharmaceuticals Sandra Turconi, Ablynx
11.45 - 12.15	Voltage-gated ion channels: Bridging the gap between Screening and Clinical development Charles Large, GSK	Is More Better - Is all Data the Same? Tina Garyantes, Sanofi-Aventis	Targeted Quantification of Cell Signalling (TIQUAS): A novel phosphoproteomics approach for biomarker discovery and drug profiling. Neil Tobett, Activiomics	The use of SPR based methods for fragment based approaches in Drug Discovery Walter Huber, F.Hoffmann-La Roche
12.15 - 12.45	Snapshots: BioFocus, Molecular Devices, Nanion, ChanTest	Snapshots: Gentronix, Pharma Diagnostics, BioTek	Snapshots: CCS , Cellectis	Snapshots: PRS, TTP Labtech, CisBio, Axxam, Fortebio, BMG Labtech
12.45 - 2.45	LUNCH, POSTERS & Exhibition
2.45 - 3.15	When FLIPR met Quattro: Screening for and optimisation of specific inhibitors of the cystic fibrosis transmembrane conductance regulator (CFTR) David Cronk, BioFocus	Attrition Reduction in Drug Discovery Alan Watt, Cellzome UK	The production of soluble protein for assay as a metaphor for the decline of  big pharma  Ceri Lewis, GSK	Biophysical Methods in the Lead Discovery Process: Combination is Key Matthias Frech, Merck Serono
3.15 - 3.45	Structure-activity relationship of the TMEM16A chloride channel protein     Luis Gallietta, Gevona	Can Fragment-Based Drug Discovery Impact Attrition ? John Barker, Evotec	Antibodies, antibody fragments and alternate binding domains in drug discovery David Humphreys, UCB	The role that High Throughput Screening plays in Drug Discovery at GSK Maite de los Frailes, GSK
3.45 - 4.15	Innovative approaches for screening TRPV1 antagonists using noxious heat as a stimulus for opening the channel Marianthi Papakosta, Pfizer	Physicochemical Properties and Drug Attrition Paul Leeson, AZ	SBDD and Biophysical Screening using stabilised GPCRs Ben Tehan, Heptares	Enhancing Hit Finding, Hit Validation and Lead Optimisation by Modern Compound Profiling  Lorenz Mayr, Novartis
4.15 - 5.15	POSTER  PRESENTATIONS
5.15 - 7.15 7.00 - 10.30	DRINKS RECEPTION     'Band and Bites'  -  Sponsored by High Res BioSolutions  -  Band and Food in Sky Creations Lounge

 

DAY 2 - 2ND SEPTEMBER 2010

	High Throughput Molecular Biology	Signalling Pathways:  Receptors and Enzymes	Drug Discovery Automation	Diseases in the Developing World
SPONSORS	Beckman Coulter		Caliper Life Sciences
Session Chairs 9.00 - 9.15	Isro Gloger, GSK Ray Owens, MRC OPPF	Steve Hill, Nottingham University Tim Hammonds, CRT	Ulrich Schopfer, Novartis Andy Zaayenga, LRIG	Steve Ward, L/pool School of Tropical Medicine Paul Wyatt, DDU, Dundee University
9.15 - 10.00	Experience of Sanger’s Large-Scale Production DNA Sequencing Facility Harold Swerdlow, Wellcome Trust	Intervention in and lessons from AGC protein kinases Peter Parker, CRUK	uHTCS:  ‘In Situ’ Chemistry Methodology enabled by Labcyte's ADE Technology for Ultra High-Throughput Chemical Synthesis Thomas Baiga, Salk Institute	TBC
10.00 - 10.30	Identifying potential new indications for assets using existing data and systems biology thinking.   Chris Larminie, GSK	Tumour cell responses to the MEK1/2 inhibitor Selumetinib (AZD6244); what can modelling acquired resistance tell us?  Simon Cook, Babraham Institute	The microfluidic toolbox – merging lab-on-a-chip technologies with lab automation for drug discovery Holger Becker, Germany	Lead Optimization of Novel Boron-Containing Small Molecules for the Treatment of Human African Trypanosomiasis Bob Jacobs, Scynexis
10.30 - 11.00	COFFEE BREAK
11.00 - 11.30	Unravelling cellular small molecule-protein interactions by chemical proteomics Kalus Schneider, GSK	Targeting tumour metabolism: new drug discovery challenges   Susan Critchlow, AZ	A High Throughput Approach for Global Infectious Disease Surveillance –- The High Throughput Laboratory Network (HTLN)  Chris Detter, LANL/UCLA	Phenotypic classification of compounds that block the proliferation of P. Falciparum in the blood stages Kip Guy, St Judes Hospital
11.30 - 12.00	High-throughput protein production and crystallization for structural proteomics Louise Bird,  OPPF, UK	Detection and characterisation of  sub-cellular cAMP signals Debbie Willoughby, Cambs Uni	Rapid chemogenomlough by, Cambs Uniic analysis of the HDAC protein family using high throughput profiling Sergei Romanov, Nanosyn	Whole cell HTS as a route to new antimalarials Ian Bathurst, Medicines for Malaria Venture
12.00 - 12.30	Snapshots: STFC, Oxford Expression, Beckman Coulter, Eppendorf, Exetek	Snapshots: Discoverx, Essen BioScience, Perkin Elmer	Snapshots: Caliper Life Sciences, RTS, BioTek	Snapshots:
12.30 - 2.00	LUNCH, POSTERS & Exhibition
2.00 - 2.30	Next generation PCR diagnostics Ian George, EMIGMA	Label-free live-cell imaging of GPCR function using dynamic mass redistribution (DMR) technology: exploiting pathway inhibitors to dissect complex optical response profiles Evi Kostenis, Bonn Uni	Microwell Cell Arrays for High-Content Screening  Holger Erfle, Bioquant	Novel therapeutic approaches against obligate intracellular pathogens using approved drug and natural compound libraries Ralf Altmeyer, Pasteur Inst. Shanghai, China
2.30 - 3.00	Genome-wide mutagenesis and systematic phenotyping in the mouse Prof Roger Cox, MRC	Combining multiple approaches to address 7-TM hit discovery Rochdi Bouhelal, Novartis	The Sheffield RNAi Screening Facility- Building a functional service Stephen Brown, Sheffield Uni	Screens and infectious diseases: hunting for magic bullets, millions of compounds at a time John Joslin, GNF, Novartis, US
3.00 - 3.30	COFFEE  BREAK
3.30 - 4.45	Closing Debate:  'Challenges Facing Drug Discovery'	Will the Pharmaceutical Industry be more open for innovation? Jackie Hunter, Pharmivation	New Directions in Drug Discovery Jim Hagan, GMEC
5.15 - 7.15	Close of Conference Prize Draw Adrian Kinkaid and Steve  Rees

 

---

HOTEL BOOKING

To book a Hotel room in the Coventry Area go to the link below :

Click here to book your drug discovery 2010 accomodation now

 

---